| abstract |
Provided is a compound that is activated in vivo from a compound having relatively little biological activity, that is, a so-called “prodrug” to a compound having relatively biological activity, and a method for targeted treatment of cancer using the compound. . A peptide comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- and having a cap-forming group c, fluorescein, fluorescein derivative, monosaccharide, D-amino acid at the N-terminus or C-terminus of the peptide, Alternatively, a prodrug comprising a peptide having a selection from proline imino acid, and a biologically active compound, anticancer agent or vascular disrupting agent bound to the peptide. [Selection figure] None |